The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia
- 2 January 2017
- journal article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 38 (3) , 382-391
Abstract
APS (Acta Pharmacologica Sinica), the top pharmacology research journal based in China, publishes original articles and reviews on all aspects of pharmacology and the related life sciencesKeywords
This publication has 36 references indexed in Scilit:
- Targeting the mTOR Pathway in LeukemiaJournal of Cellular Biochemistry, 2016
- Acute Myeloid Leukemia: Biologic, Prognostic, and Therapeutic Insights.2016
- Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014Clinical Lymphoma Myeloma and Leukemia, 2015
- Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemiaOncotarget, 2014
- Significance of SODD expression in childhood acute lymphoblastic leukemia and its influence on chemotherapyGenetics and Molecular Research, 2014
- A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseLeukemia, 2013
- [The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia].2006
- The Akt-mTOR tango and its relevance to cancerCancer Cell, 2005
- BAG4/SODD Protein Contains a Short BAG DomainJournal of Biological Chemistry, 2002
- Enhanced Expression of Silencer of Death Domains (SODD/BAG-4) in Pancreatic CancerBiochemical and Biophysical Research Communications, 2000